APO Research
Talk to an analyst

APO RESEARCH · REPORT

Recombinant Proteins

Recombinant protein is a manipulated form of protein encoded by recombinant DNA, which has been cloned in a foreign expression system to supports the expression of the exogenous gene. This recombinant DNA construct can be used to manufacture large quantities of useful protein products. The recombinant DNA, usually the cDNA sequence of the target protein, is designed to be under the control of a well-characterized promoter to express the target protein within the chosen host cell to achieve high-level protein expression.

Explore the product
View pricing & licenses

Product & engineering

Understand the product.

Recombinant protein is a manipulated form of protein encoded by recombinant DNA, which has been cloned in a foreign expression system to supports the expression of the exogenous gene. This recombinant DNA construct can be used to manufacture large quantities of useful protein products. The recombinant DNA, usually the cDNA sequence of the target protein, is designed to be under the control of a well-characterized promoter to express the target protein within the chosen host cell to achieve high-level protein expression.

Selected research

Market Analysis & Forecast

Global Recombinant Proteins Market Analysis and Forecast 2026-2032

31 December 2025194 pages

Choose your research edition.

Industry ResearchRecombinant Proteins Industry Research Report 2026134 pages · $2,950 USDIndustry Growth & TrendsGlobal Recombinant Proteins Industry Growth and Trends Forecast to 2032114 pages · $3,450 USDMarket StructureGlobal Recombinant Proteins Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032194 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Recombinant Proteins Market Outlook and Growth Opportunities 2026196 pages · $4,250 USDMarket Analysis & ForecastGlobal Recombinant Proteins Market Analysis and Forecast 2026-2032194 pages · $4,950 USD

Market perspective

Recombinant protein is a manipulated form of protein encoded by recombinant DNA, which has been cloned in a foreign expression system to supports the expression of the exogenous gene. This recombinant DNA construct can be used to manufacture large quantities of useful protein products. The recombinant DNA, usually the cDNA sequence of the target protein, is designed to be under the control of a well-characterized promoter to express the target protein within the chosen host cell to achieve high-level protein expression.

Abcam PLC was the largest company in the global Recombinant Proteins market, with a revenue market share of 13% in 2018.

Top 5 companies occupied 40% of the market.

Read the full market overview

By region, Europe was the biggest region, with a revenue market share over 33%, and North America ranked 2. Asia-Pacific ranked 3, and its market grew fastest.

Report Includes

This report presents an overview of global market for Recombinant Proteins, market size. Analyses of the global market trends, with historic market revenue data for 2021 - 2025, estimates for 2026, and projections of CAGR through 2032.

This report researches the key producers of Recombinant Proteins, also provides the revenue of main regions and countries. Of the upcoming market potential for Recombinant Proteins, and key regions or countries of focus to forecast this market into various segments and sub-segments. Country specific data and market value analysis for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, Middle East, Africa, and Other Countries.

This report focuses on the Recombinant Proteins revenue, market share and industry ranking of main manufacturers, data from 2021 to 2026. Identification of the major stakeholders in the global Recombinant Proteins market, and analysis of their competitive landscape and market positioning based on recent developments and segmental revenues. This report will help stakeholders to understand the competitive landscape and gain more insights and position their businesses and market strategies in a better way.

This report analyzes the segments data by Type and by Application, revenue, and growth rate, from 2021 to 2032. Evaluation and forecast the market size for Recombinant Proteins revenue, projected growth trends, production technology, application and end-user industry.

Recombinant Proteins Segment by Company

Abcam PLC

R&D Systems

Miltenyi Biotec

Thermo Fisher Scientific

Sigma Aldrich Company

GE Healthcare

Lonza

Merck KGaA

ProSpec Tany TechnoGene

Eurogentec (Kaneka Corporation)

PeproTech

BPS Bioscience

Reprocell

GenScript Biotech Corporation

Abnova Corporation

Recombinant Proteins Segment by Type

Hormones

Growth Factors

Cytokines

Plasma Protein Factor

Recombinant Metabolic Enzymes

Immune Checkpoint Regulators

Others

Recombinant Proteins Segment by Application

Biopharmaceutical Companies

Academic and Research Institutes

Contract Research Organizations

Recombinant Proteins Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Colombia

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Study Objectives

1. To analyze and research the global status and future forecast, involving growth rate (CAGR), market share, historical and forecast.

2. To present the key players, revenue, market share, and Recent Developments.

3. To split the breakdown data by regions, type, manufacturers, and Application.

4. To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify significant trends, drivers, influence factors in global and regions.

6. To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Recombinant Proteins market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Recombinant Proteins and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in market size), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Recombinant Proteins.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Introduces the report scope of the report, executive summary of different market segments (product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.

Chapter 2: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 3: Revenue of Recombinant Proteins in global and regional level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.

Chapter 4: Detailed analysis of Recombinant Proteins company competitive landscape, revenue, market share and industry ranking, latest development plan, merger, and acquisition information, etc.

Chapter 5: Provides the analysis of various market segments by type, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 6: Provides the analysis of various market segments by application, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 7: Provides profiles of key companies, introducing the basic situation of the main companies in the market in detail, including product descriptions and specifications, Recombinant Proteins revenue, gross margin, and recent development, etc.

Chapter 8: North America by type, by application and by country, revenue for each segment.

Chapter 9: Europe by type, by application and by country, revenue for each segment.

Chapter 10: China type, by application, revenue for each segment.

Chapter 11: Asia (excluding China) type, by application and by region, revenue for each segment.

Chapter 12: South America, Middle East and Africa by type, by application and by country, revenue for each segment.

Chapter 13: The main concluding insights of the report.

More report detail

Tables and figures
List of Tables Table 1. Global Recombinant Proteins Market Size Growth Rate by Type (US$ Million), 2021 VS 2025 VS 2032 Table 2. Hormones Major Player Table 3. Growth Factors Major Player Table 4. Cytokines Major Player Table 5. Plasma Protein Factor Major Player Table 6. Recombinant Metabolic Enzymes Major Player Table 7. Immune Checkpoint Regulators Major Player Table 8. Others Major Player Table 9. Global Recombinant Proteins Market Size Growth Rate by Application (US$ Million), 2021 VS 2025 VS 2032 Table 10. Biopharmaceutical Companies Major Player Table 11. Academic and Research Institutes Major Player Table 12. Contract Research Organizations Major Player Table 13. Recombinant Proteins Industry Trends Table 14. Recombinant Proteins Industry Drivers Table 15. Recombinant Proteins Industry Opportunities and Challenges Table 16. Recombinant Proteins Industry Restraints Table 17. Global Recombinant Proteins Market Size Growth Rate (CAGR) by Region (US$ Million): 2021 VS 2025 VS 2032 Table 18. Global Recombinant Proteins Market Size by Region (2021-2026) & (US$ Million) Table 19. Global Recombinant Proteins Market Share by Region (2021-2026) Table 20. Global Recombinant Proteins Market Size by Region (2027-2032) & (US$ Million) Table 21. Global Recombinant Proteins Market Share by Region (2027-2032) Table 22. Global Recombinant Proteins Revenue by Players (US$ Million) & (2021-2026) Table 23. Global Recombinant Proteins Revenue Market Share by Players (2021-2026) Table 24. Global Recombinant Proteins Key Players Ranking, 2024 VS 2025 VS 2026 Table 25. Global Recombinant Proteins Key Players Headquarters & Area Served Table 26. Global Recombinant Proteins Players, Product Type & Application Table 27. Global Recombinant Proteins Players Establishment Date Table 28. Global Players Market Concentration Ratio (CR5 and HHI) Table 29. Global Recombinant Proteins by Players Type (Tier 1, Tier 2, and Tier 3) & (Based on the Revenue of 2025) Table 30. Global Recombinant Proteins Revenue by Type 2021 VS 2025 VS 2032 (US$ Million) Table 31. Global Recombinant Proteins Revenue by Type (2021-2026) & (US$ Million) Table 32. Global Recombinant Proteins Revenue by Type (2027-2032) & (US$ Million) Table 33. Global Recombinant Proteins Revenue Market Share by Type (2021-2026) Table 34. Global Recombinant Proteins Revenue Market Share by Type (2027-2032) Table 35. Global Recombinant Proteins Revenue by Application 2021 VS 2025 VS 2032 (US$ Million) Table 36. Global Recombinant Proteins Revenue by Application (2021-2026) & (US$ Million) Table 37. Global Recombinant Proteins Revenue by Application (2027-2032) & (US$ Million) Table 38. Global Recombinant Proteins Revenue Market Share by Application (2021-2026) Table 39. Global Recombinant Proteins Revenue Market Share by Application (2027-2032) Table 40. Abcam PLC Company Information Table 41. Abcam PLC Business Overview Table 42. Abcam PLC Recombinant Proteins Revenue and Gross Margin (US$ Million) & (2021-2026) Table 43. Abcam PLC Recombinant Proteins Product Portfolio Table 44. Abcam PLC Recent Development Table 45. R&D Systems Company Information Table 46. R&D Systems Business Overview Table 47. R&D Systems Recombinant Proteins Revenue and Gross Margin (US$ Million) & (2021-2026) Table 48. R&D Systems Recombinant Proteins Product Portfolio Table 49. R&D Systems Recent Development Table 50. Miltenyi Biotec Company Information Table 51. Miltenyi Biotec Business Overview Table 52. Miltenyi Biotec Recombinant Proteins Revenue and Gross Margin (US$ Million) & (2021-2026) Table 53. Miltenyi Biotec Recombinant Proteins Product Portfolio Table 54. Miltenyi Biotec Recent Development Table 55. Thermo Fisher Scientific Company Information Table 56. Thermo Fisher Scientific Business Overview Table 57. Thermo Fisher Scientific Recombinant Proteins Revenue and Gross Margin (US$ Million) & (2021-2026) Table 58. Thermo Fisher Scientific Recombinant Proteins Product Portfolio Table 59. Thermo Fisher Scientific Recent Development Table 60. Sigma Aldrich Company Company Information Table 61. Sigma Aldrich Company Business Overview Table 62. Sigma Aldrich Company Recombinant Proteins Revenue and Gross Margin (US$ Million) & (2021-2026) Table 63. Sigma Aldrich Company Recombinant Proteins Product Portfolio Table 64. Sigma Aldrich Company Recent Development Table 65. GE Healthcare Company Information Table 66. GE Healthcare Business Overview Table 67. GE Healthcare Recombinant Proteins Revenue and Gross Margin (US$ Million) & (2021-2026) Table 68. GE Healthcare Recombinant Proteins Product Portfolio Table 69. GE Healthcare Recent Development Table 70. Lonza Company Information Table 71. Lonza Business Overview Table 72. Lonza Recombinant Proteins Revenue and Gross Margin (US$ Million) & (2021-2026) Table 73. Lonza Recombinant Proteins Product Portfolio Table 74. Lonza Recent Development Table 75. Merck KGaA Company Information Table 76. Merck KGaA Business Overview Table 77. Merck KGaA Recombinant Proteins Revenue and Gross Margin (US$ Million) & (2021-2026) Table 78. Merck KGaA Recombinant Proteins Product Portfolio Table 79. Merck KGaA Recent Development Table 80. ProSpec Tany TechnoGene Company Information Table 81. ProSpec Tany TechnoGene Business Overview Table 82. ProSpec Tany TechnoGene Recombinant Proteins Revenue and Gross Margin (US$ Million) & (2021-2026) Table 83. ProSpec Tany TechnoGene Recombinant Proteins Product Portfolio Table 84. ProSpec Tany TechnoGene Recent Development Table 85. Eurogentec (Kaneka Corporation) Company Information Table 86. Eurogentec (Kaneka Corporation) Business Overview Table 87. Eurogentec (Kaneka Corporation) Recombinant Proteins Revenue and Gross Margin (US$ Million) & (2021-2026) Table 88. Eurogentec (Kaneka Corporation) Recombinant Proteins Product Portfolio Table 89. Eurogentec (Kaneka Corporation) Recent Development Table 90. PeproTech Company Information Table 91. PeproTech Business Overview Table 92. PeproTech Recombinant Proteins Sales (M USD), Revenue (US$ Million), Price () and Gross Margin (2021-2026) Table 93. PeproTech Recombinant Proteins Product Portfolio Table 94. PeproTech Recent Development Table 95. BPS Bioscience Company Information Table 96. BPS Bioscience Business Overview Table 97. BPS Bioscience Recombinant Proteins Sales (M USD), Revenue (US$ Million), Price () and Gross Margin (2021-2026) Table 98. BPS Bioscience Recombinant Proteins Product Portfolio Table 99. BPS Bioscience Recent Development Table 100. Reprocell Company Information Table 101. Reprocell Business Overview Table 102. Reprocell Recombinant Proteins Sales (M USD), Revenue (US$ Million), Price () and Gross Margin (2021-2026) Table 103. Reprocell Recombinant Proteins Product Portfolio Table 104. Reprocell Recent Development Table 105. GenScript Biotech Corporation Company Information Table 106. GenScript Biotech Corporation Business Overview Table 107. GenScript Biotech Corporation Recombinant Proteins Sales (M USD), Revenue (US$ Million), Price () and Gross Margin (2021-2026) Table 108. GenScript Biotech Corporation Recombinant Proteins Product Portfolio Table 109. GenScript Biotech Corporation Recent Development Table 110. Abnova Corporation Company Information Table 111. Abnova Corporation Business Overview Table 112. Abnova Corporation Recombinant Proteins Sales (M USD), Revenue (US$ Million), Price () and Gross Margin (2021-2026) Table 113. Abnova Corporation Recombinant Proteins Product Portfolio Table 114. Abnova Corporation Recent Development Table 115. North America Recombinant Proteins Revenue by Type (2021-2026) & (US$ Million) Table 116. North America Recombinant Proteins Revenue by Type (2027-2032) & (US$ Million) Table 117. North America Recombinant Proteins Revenue by Application (2021-2026) & (US$ Million) Table 118. North America Recombinant Proteins Revenue by Application (2027-2032) & (US$ Million) Table 119. North America Recombinant Proteins Revenue by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 120. North America Recombinant Proteins Revenue by Country (2021-2026) & (US$ Million) Table 121. North America Recombinant Proteins Revenue by Country (US$ Million) & (2027-2032) Table 122. Europe Recombinant Proteins Revenue by Type (2021-2026) & (US$ Million) Table 123. Europe Recombinant Proteins Revenue by Type (2027-2032) & (US$ Million) Table 124. Europe Recombinant Proteins Revenue by Application (2021-2026) & (US$ Million) Table 125. Europe Recombinant Proteins Revenue by Application (2027-2032) & (US$ Million) Table 126. Europe Recombinant Proteins Revenue by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 127. Europe Recombinant Proteins Revenue by Country (2021-2026) & (US$ Million) Table 128. Europe Recombinant Proteins Revenue by Country (US$ Million) & (2027-2032) Table 129. China Recombinant Proteins Revenue by Type (2021-2026) & (US$ Million) Table 130. China Recombinant Proteins Revenue by Type (2027-2032) & (US$ Million) Table 131. China Recombinant Proteins Revenue by Application (2021-2026) & (US$ Million) Table 132. China Recombinant Proteins Revenue by Application (2027-2032) & (US$ Million) Table 133. Asia Recombinant Proteins Revenue by Type (2021-2026) & (US$ Million) Table 134. Asia Recombinant Proteins Revenue by Type (2027-2032) & (US$ Million) Table 135. Asia Recombinant Proteins Revenue by Application (2021-2026) & (US$ Million) Table 136. Asia Recombinant Proteins Revenue by Application (2027-2032) & (US$ Million) Table 137. Asia Recombinant Proteins Revenue by Region (2021 VS 2025 VS 2032) & (US$ Million) Table 138. Asia Recombinant Proteins Revenue by Region (US$ Million) & (2021-2026) Table 139. Asia Recombinant Proteins Revenue by Region (US$ Million) & (2027-2032) Table 140. SAMEA Recombinant Proteins Revenue by Type (2021-2026) & (US$ Million) Table 141. SAMEA Recombinant Proteins Revenue by Type (2027-2032) & (US$ Million) Table 142. SAMEA Recombinant Proteins Revenue by Application (2021-2026) & (US$ Million) Table 143. SAMEA Recombinant Proteins Revenue by Application (2027-2032) & (US$ Million) Table 144. SAMEA Recombinant Proteins Revenue by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 145. SAMEA Recombinant Proteins Revenue by Country (2021-2026) & (US$ Million) Table 146. SAMEA Recombinant Proteins Revenue by Country (US$ Million) & (2027-2032) Table 147. Research Programs/Design for This Report Table 148. Authors List of This Report Table 149. Secondary Sources Table 150. Primary Sources List of Figures Figure 1. Recombinant Proteins Image Figure 2. Global Recombinant Proteins Market Size Growth Rate by Type (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Recombinant Proteins Market Size Share 2021 VS 2025 VS 2032 Figure 4. Hormones Image Figure 5. Growth Factors Image Figure 6. Cytokines Image Figure 7. Plasma Protein Factor Image Figure 8. Recombinant Metabolic Enzymes Image Figure 9. Immune Checkpoint Regulators Image Figure 10. Others Image Figure 11. Global Recombinant Proteins Market Size Growth Rate by Application (US$ Million), 2021 VS 2025 VS 2032 Figure 12. Global Recombinant Proteins Market Size Share 2021 VS 2025 VS 2032 Figure 13. Biopharmaceutical Companies Image Figure 14. Academic and Research Institutes Image Figure 15. Contract Research Organizations Image Figure 16. Global Recombinant Proteins Market Size (US$ Million) & (2021-2032) Figure 17. Global Recombinant Proteins Market Size, (US$ Million), 2021 VS 2025 VS 2032 Figure 18. Global Recombinant Proteins Market Share by Region: 2021 VS 2025 VS 2032 Figure 19. Global Recombinant Proteins Players Revenue Share Top 10 and Top 5 in 2025 Figure 20. Players Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 21. Global Recombinant Proteins Revenue by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 22. Global Recombinant Proteins Revenue Market Share 2021 VS 2025 VS 2032 Figure 23. Global Recombinant Proteins Revenue Market Share by Type (2021-2032) Figure 24. Global Recombinant Proteins Revenue by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 25. Global Recombinant Proteins Revenue Market Share by Application (2021 VS 2025 VS 2032) Figure 26. Global Recombinant Proteins Revenue Market Share by Application (2021-2032) Figure 27. North America Recombinant Proteins Revenue YoY Growth (2021-2032) & (US$ Million) Figure 28. North America Recombinant Proteins Revenue Share by Type (2021-2032) Figure 29. North America Recombinant Proteins Revenue Share by Application (2021-2032) Figure 30. North America Recombinant Proteins Revenue Share by Country (2021-2032) Figure 31. United States Recombinant Proteins Revenue YoY Growth (US$ Million) & (2021-2032) Figure 32. Canada Recombinant Proteins Revenue YoY Growth (US$ Million) & (2021-2032) Figure 33. Mexico Recombinant Proteins Revenue YoY Growth (US$ Million) & (2021-2032) Figure 34. Europe Recombinant Proteins Revenue YoY Growth (2021-2032) & (US$ Million) Figure 35. Europe Recombinant Proteins Revenue Share by Type (2021-2032) Figure 36. Europe Recombinant Proteins Revenue Share by Application (2021-2032) Figure 37. Europe Recombinant Proteins Revenue Share by Country (2021-2032) Figure 38. Germany Recombinant Proteins Revenue YoY Growth (US$ Million) & (2021-2032) Figure 39. France Recombinant Proteins Revenue YoY Growth (US$ Million) & (2021-2032) Figure 40. U.K. Recombinant Proteins Revenue YoY Growth (US$ Million) & (2021-2032) Figure 41. Italy Recombinant Proteins Revenue YoY Growth (US$ Million) & (2021-2032) Figure 42. Spain Recombinant Proteins Revenue YoY Growth (US$ Million) & (2021-2032) Figure 43. Russia Recombinant Proteins Revenue YoY Growth (US$ Million) & (2021-2032) Figure 44. Netherlands Recombinant Proteins Revenue YoY Growth (US$ Million) & (2021-2032) Figure 45. Nordic Countries Recombinant Proteins Revenue YoY Growth (US$ Million) & (2021-2032) Figure 46. China Recombinant Proteins Revenue YoY Growth (2021-2032) & (US$ Million) Figure 47. China Recombinant Proteins Revenue Share by Type (2021-2032) Figure 48. China Recombinant Proteins Revenue Share by Application (2021-2032) Figure 49. Asia Recombinant Proteins Revenue YoY Growth (2021-2032) & (US$ Million) Figure 50. Asia Recombinant Proteins Revenue Share by Type (2021-2032) Figure 51. Asia Recombinant Proteins Revenue Share by Application (2021-2032) Figure 52. Asia Recombinant Proteins Revenue Share by Region (2021-2032) Figure 53. Japan Recombinant Proteins Revenue YoY Growth (US$ Million) & (2021-2032) Figure 54. South Korea Recombinant Proteins Revenue YoY Growth (US$ Million) & (2021-2032) Figure 55. India Recombinant Proteins Revenue YoY Growth (US$ Million) & (2021-2032) Figure 56. Australia Recombinant Proteins Revenue YoY Growth (US$ Million) & (2021-2032) Figure 57. Taiwan Recombinant Proteins Revenue YoY Growth (US$ Million) & (2021-2032) Figure 58. Southeast Asia Recombinant Proteins Revenue YoY Growth (US$ Million) & (2021-2032) Figure 59. SAMEA Recombinant Proteins Revenue YoY Growth (2021-2032) & (US$ Million) Figure 60. SAMEA Recombinant Proteins Revenue Share by Type (2021-2032) Figure 61. SAMEA Recombinant Proteins Revenue Share by Application (2021-2032) Figure 62. SAMEA Recombinant Proteins Revenue Share by Country (2021-2032) Figure 63. Brazil Recombinant Proteins Revenue YoY Growth (US$ Million) & (2021-2032) Figure 64. Argentina Recombinant Proteins Revenue YoY Growth (US$ Million) & (2021-2032) Figure 65. Chile Recombinant Proteins Revenue YoY Growth (US$ Million) & (2021-2032) Figure 66. Colombia Recombinant Proteins Revenue YoY Growth (US$ Million) & (2021-2032) Figure 67. Peru Recombinant Proteins Revenue YoY Growth (US$ Million) & (2021-2032) Figure 68. Saudi Arabia Recombinant Proteins Revenue YoY Growth (US$ Million) & (2021-2032) Figure 69. Israel Recombinant Proteins Revenue YoY Growth (US$ Million) & (2021-2032) Figure 70. UAE Recombinant Proteins Revenue YoY Growth (US$ Million) & (2021-2032) Figure 71. Turkey Recombinant Proteins Revenue YoY Growth (US$ Million) & (2021-2032) Figure 72. Iran Recombinant Proteins Revenue YoY Growth (US$ Million) & (2021-2032) Figure 73. Egypt Recombinant Proteins Revenue YoY Growth (US$ Million) & (2021-2032) Figure 74. Years Considered Figure 75. Research Process Figure 76. Key Executives Interviewed

Scope & coverage.

Types
  • Hormones
  • Growth Factors
  • Cytokines
  • Plasma Protein Factor
  • Recombinant Metabolic Enzymes
  • Immune Checkpoint Regulators
  • Others
Applications
  • Biopharmaceutical Companies
  • Academic and Research Institutes
  • Contract Research Organizations
Companies covered
  • Abcam PLC
  • R&D Systems
  • Miltenyi Biotec
  • Thermo Fisher Scientific
  • Sigma Aldrich Company
  • GE Healthcare
  • Lonza
  • Merck KGaA
  • ProSpec Tany TechnoGene
  • Eurogentec (Kaneka Corporation)
  • PeproTech
  • BPS Bioscience
  • Reprocell
  • GenScript Biotech Corporation
  • Abnova Corporation

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Recombinant Proteins Market by Type
  3. 1.2.1 Global Recombinant Proteins Market Size by Type, 2021 VS 2025 VS 2032
  4. 1.2.2 Hormones
  5. 1.2.3 Growth Factors
  6. 1.2.4 Cytokines
  7. 1.2.5 Plasma Protein Factor
  8. 1.2.6 Recombinant Metabolic Enzymes
  9. 1.2.7 Immune Checkpoint Regulators
  10. 1.2.8 Others
  11. 1.3 Recombinant Proteins Market by Application
  12. 1.3.1 Global Recombinant Proteins Market Size by Application, 2021 VS 2025 VS 2032
  13. 1.3.2 Biopharmaceutical Companies
  14. 1.3.3 Academic and Research Institutes
  15. 1.3.4 Contract Research Organizations
  16. 1.4 Assumptions and Limitations
  17. 1.5 Study Goals and Objectives
2 Recombinant Proteins Market Dynamics
  1. 2.1 Recombinant Proteins Industry Trends
  2. 2.2 Recombinant Proteins Industry Drivers
  3. 2.3 Recombinant Proteins Industry Opportunities and Challenges
  4. 2.4 Recombinant Proteins Industry Restraints
3 Global Growth Perspective
  1. 3.1 Global Recombinant Proteins Market Perspective (2021-2032)
  2. 3.2 Global Recombinant Proteins Growth Trends by Region
  3. 3.2.1 Global Recombinant Proteins Market Size by Region: 2021 VS 2025 VS 2032
  4. 3.2.2 Global Recombinant Proteins Market Size by Region (2021-2026)
  5. 3.2.3 Global Recombinant Proteins Market Size by Region (2027-2032)
4 Competitive Landscape by Players
  1. 4.1 Global Recombinant Proteins Revenue by Players
  2. 4.1.1 Global Recombinant Proteins Revenue by Players (2021-2026)
  3. 4.1.2 Global Recombinant Proteins Revenue Market Share by Players (2021-2026)
  4. 4.1.3 Global Recombinant Proteins Players Revenue Share Top 10 and Top 5 in 2025
  5. 4.2 Global Recombinant Proteins Key Players Ranking, 2024 VS 2025 VS 2026
  6. 4.3 Global Recombinant Proteins Key Players Headquarters & Area Served
  7. 4.4 Global Recombinant Proteins Players, Product Type & Application
  8. 4.5 Global Recombinant Proteins Players Establishment Date
  9. 4.6 Market Competitive Analysis
  10. 4.6.1 Global Recombinant Proteins Market CR5 and HHI
  11. 4.6.3 2025 Recombinant Proteins Tier 1, Tier 2, and Tier 3
5 Recombinant Proteins Market Size by Type
  1. 5.1 Global Recombinant Proteins Revenue by Type (2021 VS 2025 VS 2032)
  2. 5.2 Global Recombinant Proteins Revenue by Type (2021-2032)
  3. 5.3 Global Recombinant Proteins Revenue Market Share by Type (2021-2032)
6 Recombinant Proteins Market Size by Application
  1. 6.1 Global Recombinant Proteins Revenue by Application (2021 VS 2025 VS 2032)
  2. 6.2 Global Recombinant Proteins Revenue by Application (2021-2032)
  3. 6.3 Global Recombinant Proteins Revenue Market Share by Application (2021-2032)
7 Company Profiles
  1. 7.1 Abcam PLC
  2. 7.1.1 Abcam PLC Company Information
  3. 7.1.2 Abcam PLC Business Overview
  4. 7.1.3 Abcam PLC Recombinant Proteins Revenue and Gross Margin (2021-2026)
  5. 7.1.4 Abcam PLC Recombinant Proteins Product Portfolio
  6. 7.1.5 Abcam PLC Recent Developments
  7. 7.2 R&D Systems
  8. 7.2.1 R&D Systems Company Information
  9. 7.2.2 R&D Systems Business Overview
  10. 7.2.3 R&D Systems Recombinant Proteins Revenue and Gross Margin (2021-2026)
  11. 7.2.4 R&D Systems Recombinant Proteins Product Portfolio
  12. 7.2.5 R&D Systems Recent Developments
  13. 7.3 Miltenyi Biotec
  14. 7.3.1 Miltenyi Biotec Company Information
  15. 7.3.2 Miltenyi Biotec Business Overview
  16. 7.3.3 Miltenyi Biotec Recombinant Proteins Revenue and Gross Margin (2021-2026)
  17. 7.3.4 Miltenyi Biotec Recombinant Proteins Product Portfolio
  18. 7.3.5 Miltenyi Biotec Recent Developments
  19. 7.4 Thermo Fisher Scientific
  20. 7.4.1 Thermo Fisher Scientific Company Information
  21. 7.4.2 Thermo Fisher Scientific Business Overview
  22. 7.4.3 Thermo Fisher Scientific Recombinant Proteins Revenue and Gross Margin (2021-2026)
  23. 7.4.4 Thermo Fisher Scientific Recombinant Proteins Product Portfolio
  24. 7.4.5 Thermo Fisher Scientific Recent Developments
  25. 7.5 Sigma Aldrich Company
  26. 7.5.1 Sigma Aldrich Company Company Information
  27. 7.5.2 Sigma Aldrich Company Business Overview
  28. 7.5.3 Sigma Aldrich Company Recombinant Proteins Revenue and Gross Margin (2021-2026)
  29. 7.5.4 Sigma Aldrich Company Recombinant Proteins Product Portfolio
  30. 7.5.5 Sigma Aldrich Company Recent Developments
  31. 7.6 GE Healthcare
  32. 7.6.1 GE Healthcare Company Information
  33. 7.6.2 GE Healthcare Business Overview
  34. 7.6.3 GE Healthcare Recombinant Proteins Revenue and Gross Margin (2021-2026)
  35. 7.6.4 GE Healthcare Recombinant Proteins Product Portfolio
  36. 7.6.5 GE Healthcare Recent Developments
  37. 7.7 Lonza
  38. 7.7.1 Lonza Company Information
  39. 7.7.2 Lonza Business Overview
  40. 7.7.3 Lonza Recombinant Proteins Revenue and Gross Margin (2021-2026)
  41. 7.7.4 Lonza Recombinant Proteins Product Portfolio
  42. 7.7.5 Lonza Recent Developments
  43. 7.8 Merck KGaA
  44. 7.8.1 Merck KGaA Company Information
  45. 7.8.2 Merck KGaA Business Overview
  46. 7.8.3 Merck KGaA Recombinant Proteins Revenue and Gross Margin (2021-2026)
  47. 7.8.4 Merck KGaA Recombinant Proteins Product Portfolio
  48. 7.8.5 Merck KGaA Recent Developments
  49. 7.9 ProSpec Tany TechnoGene
  50. 7.9.1 ProSpec Tany TechnoGene Company Information
  51. 7.9.2 ProSpec Tany TechnoGene Business Overview
  52. 7.9.3 ProSpec Tany TechnoGene Recombinant Proteins Revenue and Gross Margin (2021-2026)
  53. 7.9.4 ProSpec Tany TechnoGene Recombinant Proteins Product Portfolio
  54. 7.9.5 ProSpec Tany TechnoGene Recent Developments
  55. 7.10 Eurogentec (Kaneka Corporation)
  56. 7.10.1 Eurogentec (Kaneka Corporation) Company Information
  57. 7.10.2 Eurogentec (Kaneka Corporation) Business Overview
  58. 7.10.3 Eurogentec (Kaneka Corporation) Recombinant Proteins Revenue and Gross Margin (2021-2026)
  59. 7.10.4 Eurogentec (Kaneka Corporation) Recombinant Proteins Product Portfolio
  60. 7.10.5 Eurogentec (Kaneka Corporation) Recent Developments
  61. 7.11 PeproTech
  62. 7.11.1 PeproTech Company Information
  63. 7.11.2 PeproTech Business Overview
  64. 7.11.3 PeproTech Recombinant Proteins Revenue and Gross Margin (2021-2026)
  65. 7.11.4 PeproTech Recombinant Proteins Product Portfolio
  66. 7.11.5 PeproTech Recent Developments
  67. 7.12 BPS Bioscience
  68. 7.12.1 BPS Bioscience Company Information
  69. 7.12.2 BPS Bioscience Business Overview
  70. 7.12.3 BPS Bioscience Recombinant Proteins Revenue and Gross Margin (2021-2026)
  71. 7.12.4 BPS Bioscience Recombinant Proteins Product Portfolio
  72. 7.12.5 BPS Bioscience Recent Developments
  73. 7.13 Reprocell
  74. 7.13.1 Reprocell Company Information
  75. 7.13.2 Reprocell Business Overview
  76. 7.13.3 Reprocell Recombinant Proteins Revenue and Gross Margin (2021-2026)
  77. 7.13.4 Reprocell Recombinant Proteins Product Portfolio
  78. 7.13.5 Reprocell Recent Developments
  79. 7.14 GenScript Biotech Corporation
  80. 7.14.1 GenScript Biotech Corporation Company Information
  81. 7.14.2 GenScript Biotech Corporation Business Overview
  82. 7.14.3 GenScript Biotech Corporation Recombinant Proteins Revenue and Gross Margin (2021-2026)
  83. 7.14.4 GenScript Biotech Corporation Recombinant Proteins Product Portfolio
  84. 7.14.5 GenScript Biotech Corporation Recent Developments
  85. 7.15 Abnova Corporation
  86. 7.15.1 Abnova Corporation Company Information
  87. 7.15.2 Abnova Corporation Business Overview
  88. 7.15.3 Abnova Corporation Recombinant Proteins Revenue and Gross Margin (2021-2026)
  89. 7.15.4 Abnova Corporation Recombinant Proteins Product Portfolio
  90. 7.15.5 Abnova Corporation Recent Developments
8 North America
  1. 8.1 North America Recombinant Proteins Revenue (2021-2032)
  2. 8.2 North America Recombinant Proteins Revenue by Type (2021-2032)
  3. 8.2.1 North America Recombinant Proteins Revenue by Type (2021-2026)
  4. 8.2.2 North America Recombinant Proteins Revenue by Type (2027-2032)
  5. 8.3 North America Recombinant Proteins Revenue Share by Type (2021-2032)
  6. 8.4 North America Recombinant Proteins Revenue by Application (2021-2032)
  7. 8.4.1 North America Recombinant Proteins Revenue by Application (2021-2026)
  8. 8.4.2 North America Recombinant Proteins Revenue by Application (2027-2032)
  9. 8.5 North America Recombinant Proteins Revenue Share by Application (2021-2032)
  10. 8.6 North America Recombinant Proteins Revenue by Country
  11. 8.6.1 North America Recombinant Proteins Revenue by Country (2021 VS 2025 VS 2032)
  12. 8.6.2 North America Recombinant Proteins Revenue by Country (2021-2026)
  13. 8.6.3 North America Recombinant Proteins Revenue by Country (2027-2032)
  14. 8.6.4 United States
  15. 8.6.5 Canada
  16. 8.6.6 Mexico
9 Europe
  1. 9.1 Europe Recombinant Proteins Revenue (2021-2032)
  2. 9.2 Europe Recombinant Proteins Revenue by Type (2021-2032)
  3. 9.2.1 Europe Recombinant Proteins Revenue by Type (2021-2026)
  4. 9.2.2 Europe Recombinant Proteins Revenue by Type (2027-2032)
  5. 9.3 Europe Recombinant Proteins Revenue Share by Type (2021-2032)
  6. 9.4 Europe Recombinant Proteins Revenue by Application (2021-2032)
  7. 9.4.1 Europe Recombinant Proteins Revenue by Application (2021-2026)
  8. 9.4.2 Europe Recombinant Proteins Revenue by Application (2027-2032)
  9. 9.5 Europe Recombinant Proteins Revenue Share by Application (2021-2032)
  10. 9.6 Europe Recombinant Proteins Revenue by Country
  11. 9.6.1 Europe Recombinant Proteins Revenue by Country (2021 VS 2025 VS 2032)
  12. 9.6.2 Europe Recombinant Proteins Revenue by Country (2021-2026)
  13. 9.6.3 Europe Recombinant Proteins Revenue by Country (2027-2032)
  14. 9.6.4 Germany
  15. 9.6.5 France
  16. 9.6.6 U.K.
  17. 9.6.7 Italy
  18. 9.6.8 Russia
  19. 9.6.9 Spain
  20. 9.6.10 Netherlands
  21. 9.6.11 Switzerland
  22. 9.6.12 Sweden
  23. 9.6.13 Poland
10 China
  1. 10.1 China Recombinant Proteins Revenue (2021-2032)
  2. 10.2 China Recombinant Proteins Revenue by Type (2021-2032)
  3. 10.2.1 China Recombinant Proteins Revenue by Type (2021-2026)
  4. 10.2.2 China Recombinant Proteins Revenue by Type (2027-2032)
  5. 10.3 China Recombinant Proteins Revenue Share by Type (2021-2032)
  6. 10.4 China Recombinant Proteins Revenue by Application (2021-2032)
  7. 10.4.1 China Recombinant Proteins Revenue by Application (2021-2026)
  8. 10.4.2 China Recombinant Proteins Revenue by Application (2027-2032)
  9. 10.5 China Recombinant Proteins Revenue Share by Application (2021-2032)
11 Asia (Excluding China)
  1. 11.1 Asia Recombinant Proteins Revenue (2021-2032)
  2. 11.2 Asia Recombinant Proteins Revenue by Type (2021-2032)
  3. 11.2.1 Asia Recombinant Proteins Revenue by Type (2021-2026)
  4. 11.2.2 Asia Recombinant Proteins Revenue by Type (2027-2032)
  5. 11.3 Asia Recombinant Proteins Revenue Share by Type (2021-2032)
  6. 11.4 Asia Recombinant Proteins Revenue by Application (2021-2032)
  7. 11.4.1 Asia Recombinant Proteins Revenue by Application (2021-2026)
  8. 11.4.2 Asia Recombinant Proteins Revenue by Application (2027-2032)
  9. 11.5 Asia Recombinant Proteins Revenue Share by Application (2021-2032)
  10. 11.6 Asia Recombinant Proteins Revenue by Country
  11. 11.6.1 Asia Recombinant Proteins Revenue by Country (2021 VS 2025 VS 2032)
  12. 11.6.2 Asia Recombinant Proteins Revenue by Country (2021-2026)
  13. 11.6.3 Asia Recombinant Proteins Revenue by Country (2027-2032)
  14. 11.6.4 Japan
  15. 11.6.5 South Korea
  16. 11.6.6 India
  17. 11.6.7 Australia
  18. 11.6.8 Taiwan
  19. 11.6.9 Southeast Asia
12 South America, Middle East and Africa
  1. 12.1 SAMEA Recombinant Proteins Revenue (2021-2032)
  2. 12.2 SAMEA Recombinant Proteins Revenue by Type (2021-2032)
  3. 12.2.1 SAMEA Recombinant Proteins Revenue by Type (2021-2026)
  4. 12.2.2 SAMEA Recombinant Proteins Revenue by Type (2027-2032)
  5. 12.3 SAMEA Recombinant Proteins Revenue Share by Type (2021-2032)
  6. 12.4 SAMEA Recombinant Proteins Revenue by Application (2021-2032)
  7. 12.4.1 SAMEA Recombinant Proteins Revenue by Application (2021-2026)
  8. 12.4.2 SAMEA Recombinant Proteins Revenue by Application (2027-2032)
  9. 12.5 SAMEA Recombinant Proteins Revenue Share by Application (2021-2032)
  10. 12.6 SAMEA Recombinant Proteins Revenue by Country
  11. 12.6.1 SAMEA Recombinant Proteins Revenue by Country (2021 VS 2025 VS 2032)
  12. 12.6.2 SAMEA Recombinant Proteins Revenue by Country (2021-2026)
  13. 12.6.3 SAMEA Recombinant Proteins Revenue by Country (2027-2032)
  14. 12.6.4 Brazil
  15. 12.6.5 Argentina
  16. 12.6.6 Chile
  17. 12.6.7 Colombia
  18. 12.6.8 Peru
  19. 12.6.9 Saudi Arabia
  20. 12.6.10 Israel
  21. 12.6.11 UAE
  22. 12.6.12 Turkey
  23. 12.6.13 Iran
  24. 12.6.14 Egypt
13 Concluding Insights
    14 Appendix
    1. 14.1 Reasons for Doing This Study
    2. 14.2 Research Methodology
    3. 14.3 Research Process
    4. 14.4 Authors List of This Report
    5. 14.5 Data Source
    6. 14.5.1 Secondary Sources
    7. 14.5.2 Primary Sources

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $4,950USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst